Pharmaceuticals company Themis Medicare announced Q2FY26 results Revenue: Rs 78.0 crore against Rs 117.0 crore during Q2FY25. EBITDA: Rs -3.1 crore against Rs 17.1 crore during Q2FY25. EBITDA Margin: -4.0% for Q2FY26. PAT: Rs -3.6 crore against Rs 14.3 crore during Q2FY25. PAT Margin: -4.6% for Q2FY26. EPS: Rs -0.39 for Q2FY26. Sachin Patel, Managing Director & CEO, said: “The Company continued to face headwinds from disruption in a high margin major line of Business since the last two quarters. In this regard, regulators are currently investigating the matter and we expect a positive development on this by March 2026. Despite the headwinds, our API business grew 31% year-on-year in the half-year period, while Trade business increased 4%. As part of our Hospital business, we aim to increase our focus on high margin brands and products. Moving forward, we are striving to improve operational efficiency, cost optimization, field force productivity, and working capital management. Our R&D; pipeline continues to be strong, and we will keep directing our efforts into creating differentiated products in critical therapeutic areas. Consolidated revenue for the quarter was reported at Rs 78 crore; muted performance in the formulations business hampered profitability. The Company remains resilient and we are cautiously optimistic based on our core competence and overall market opportunity.” Result PDF